PNCRM9

Developed for: pneumococcal infection · otitis media
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID)

today NCT00133549 · Ph 2

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00133549	Nov 2000 → Dec 2002	pneumococcal infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT00617682 Comparator	Oct 2000 → Dec 2004	otitis media	National Institute on Deafness and Other Communication Disorders (NIDCD)	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	PNCRM9	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00617682 ↗ 1 NCT00133549 ↗
Known as	9-valent pneumococcal conjugate vaccine	“A randomized trial of an investigational 9-valent pneumococcal conjugate vaccine (PCV-9) or placebo given to pregnant women during the last trimester to prevent early infant...” PMID 25444821 ↗ Oct 2014
Known as	Nine-valent pneumococcal conjugate	“Nine-valent pneumococcal conjugate (PNCRM9)” NCT00133549 ↗
Known as	PCV-9	“A randomized trial of an investigational 9-valent pneumococcal conjugate vaccine (PCV-9) or placebo given to pregnant women during the last trimester to prevent early infant...” PMID 25444821 ↗ Oct 2014
Modality	Vaccine	“Vaccine is prepared from pneumococcal polysaccharides” NCT00133549 ↗
Route	Intramuscular	“The vaccine will be administered in a volume of 0.5 ml intramuscularly.” NCT00133549 ↗